BRPI0911098A2 - formulação lipossomal e método para tratamento de bexiga hiperativa. - Google Patents

formulação lipossomal e método para tratamento de bexiga hiperativa.

Info

Publication number
BRPI0911098A2
BRPI0911098A2 BRPI0911098A BRPI0911098A BRPI0911098A2 BR PI0911098 A2 BRPI0911098 A2 BR PI0911098A2 BR PI0911098 A BRPI0911098 A BR PI0911098A BR PI0911098 A BRPI0911098 A BR PI0911098A BR PI0911098 A2 BRPI0911098 A2 BR PI0911098A2
Authority
BR
Brazil
Prior art keywords
overactive bladder
liposomal formulation
treating overactive
treating
liposomal
Prior art date
Application number
BRPI0911098A
Other languages
English (en)
Inventor
Jonathan H Kaufman
Michael B Chancellor
Original Assignee
Lipella Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipella Pharmaceuticals Inc filed Critical Lipella Pharmaceuticals Inc
Publication of BRPI0911098A2 publication Critical patent/BRPI0911098A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0911098A 2008-04-04 2009-04-03 formulação lipossomal e método para tratamento de bexiga hiperativa. BRPI0911098A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4253608P 2008-04-04 2008-04-04
US11026608P 2008-10-31 2008-10-31
PCT/US2009/039489 WO2009139984A2 (en) 2008-04-04 2009-04-03 Method of treatment for bladder dysfunction

Publications (1)

Publication Number Publication Date
BRPI0911098A2 true BRPI0911098A2 (pt) 2015-10-06

Family

ID=41319235

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911098A BRPI0911098A2 (pt) 2008-04-04 2009-04-03 formulação lipossomal e método para tratamento de bexiga hiperativa.

Country Status (10)

Country Link
US (1) US20120093920A1 (pt)
EP (2) EP2273976A2 (pt)
JP (2) JP5538359B2 (pt)
KR (1) KR20100131471A (pt)
CN (1) CN102065841A (pt)
AU (1) AU2009246834B2 (pt)
BR (1) BRPI0911098A2 (pt)
CA (1) CA2720523C (pt)
MX (1) MX2010010635A (pt)
WO (1) WO2009139984A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
JP6470678B2 (ja) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド ニューロンの開口分泌を阻害する化合物（ｉｉ）
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
PL2890384T3 (pl) 2012-08-31 2022-02-14 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę
WO2014036556A2 (en) 2012-08-31 2014-03-06 Taris Biomedical, Inc. Drug delivery systems and methods for treatment of prostate
EP3060197B1 (en) 2013-10-22 2023-06-07 Lipella Pharmaceuticals Inc. Delivery of agents using metastable liposomes
PT3113782T (pt) 2014-03-06 2023-01-05 Taris Biomedical Llc Sistemas e métodos de administração de fármaco para tratamento do cancro da bexiga com gemcitabina
US20160045623A1 (en) 2015-04-03 2016-02-18 Lipella Pharmaceuticals, Inc. Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI)
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
KR102892737B1 (ko) 2017-11-08 2025-11-28 타리스 바이오메디컬 엘엘씨 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
KR102398743B1 (ko) * 2020-09-03 2022-05-16 충남대학교병원 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물
TWI760996B (zh) * 2020-12-25 2022-04-11 姜秉均 含有疏水性物質的奈米組成物及其製備方法與用途
CN117883383A (zh) * 2023-12-26 2024-04-16 中国康复研究中心 一种作为A型肉毒素载体的TiO2纳米粒子及制备方法
US12272439B1 (en) 2024-05-06 2025-04-08 Immunitybio, Inc. Distributed ledger for medicament administration tracking

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693209B2 (ja) * 1996-04-11 2005-09-07 三菱化学株式会社 閉鎖小胞の製造方法
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
AU2003259246A1 (en) 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
WO2007044748A2 (en) 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders

Also Published As

Publication number Publication date
CA2720523A1 (en) 2009-11-19
AU2009246834B2 (en) 2012-12-06
KR20100131471A (ko) 2010-12-15
WO2009139984A3 (en) 2010-03-04
EP2599476A1 (en) 2013-06-05
JP5538359B2 (ja) 2014-07-02
EP2273976A2 (en) 2011-01-19
MX2010010635A (es) 2010-12-17
CN102065841A (zh) 2011-05-18
US20120093920A1 (en) 2012-04-19
CA2720523C (en) 2013-12-17
WO2009139984A2 (en) 2009-11-19
JP2014062125A (ja) 2014-04-10
JP2011516497A (ja) 2011-05-26
AU2009246834A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
BRPI0916472A2 (pt) dispositivo de tratamento de ferimento, método para tratamento de um ferimento e dispositivo de tratamento de ferimento
PT3058875T (pt) Sistema para tratamento cosmético e imagiologia
BR112012000882A2 (pt) Preparação cosmética capilar e método para aplicação.
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI0817292A2 (pt) Método e aparelho para completação de poços.
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0910723A2 (pt) aparelho e método de frenagem.
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI0917358A2 (pt) formulação farmacêutica de liberação controlada e método.
BRPI0912934A2 (pt) aparelho e método
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0910713A2 (pt) método e aparelhos
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0908715A2 (pt) métodos para tratamento da psoríase
BR112012027145A2 (pt) emulsão, composição de uso final e método para tratar uma condição cutânea
BRPI0914120A2 (pt) método e aparelho para determinação estrutural
BRPI0823290A2 (pt) Método e aparelho para configuração de dispositivos.
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BRPI0907150A2 (pt) Dispositivo e método para microelastografia
BRPI0907227A2 (pt) Método e dispositivo para assinatura
BRPI0823238A2 (pt) Composição, e, método

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.